Cathie Wood's Investment Moves on March 25! Increased Buying... On March 25, Cathie Wood’s ARK Invest made significant adjustments to its portfolio, reflecting a strategic shift in focus amid evolving market dynamics. The firm’s trading activities highlighted a stark contrast between buying and selling, with only one stock purchased while 18 companies were divested. The decision underscores ARK’s efforts to streamline its holdings and prioritize assets with stronger long-term potential. The sole stock added to ARK’s portfolio was Tempus AI (TEM.US), where the firm increased its holdings by 84,900 shares. This move aligns with ARK’s broader confidence in AI healthcare’s next phase, where companies possessing extensive multimodal clinical and molecular data are expected to lead. By focusing on TEM, ARK is emphasizing proprietary data infrastructure as a critical competitive advantage, moving away from tool-based firms and concept-driven stocks. On the selling side, ARK’s portfolio saw a broad exodus across multiple sectors. The largest sale targeted Japan’s internet giant LY (4689.JP), with over 2.11 million shares offloaded. Other notable exits included Pinterest (PINS.US), Roku Inc (ROKU.US), and Meta Platforms (META.US), reflecting a reduced valuation of traditional Web 2.0 companies. ARK’s actions signal a shift away from conventional monetization models in social media, streaming, and super apps, which are increasingly challenged by AI-generated content. In healthcare, ARK trimmed positions in AI drug discovery and gene-editing firms, including Beam Therapeutics (BEAM.US), Illumina (ILMN.US), and Natera (NTRA.US). This reduction contrasts with the focus on TEM, indicating a narrowing of healthcare investments to companies with shorter commercialization timelines and clearer data monetization potential.#ark_invest #cathie_wood #tempus_ai #ly_4689_jp #pinterest_pins_us
ARK Invest Exits Meta and Roku Positions While Increasing Stake in Tempus AI Cathie Wood’s ARK Invest executed a strategic portfolio rebalancing on Wednesday, March 25, reducing exposure to Meta and Roku while significantly increasing its position in healthcare artificial intelligence firm Tempus AI. The investment firm sold 3,578 Meta shares valued at approximately $2.1 million across three funds, bringing its remaining holdings in the ARK Innovation ETF to roughly 105,000 shares, currently worth about $63 million. This represents roughly 1% of the fund’s total assets. ARK also divested 95,090 Roku shares, generating proceeds of around $9.1 million through its ARKK, ARKW, and ARKF funds. This sale follows a prior significant Roku divestment on March 24, continuing a trend of reducing exposure to the streaming company. Additional disposals included 30,174 Teradyne shares valued at $9.7 million and 205,019 Bullish shares totaling about $7.7 million across three ETFs. The firm has been systematically reducing its Bullish position over the past week. Simultaneously, ARK purchased 84,939 Tempus AI shares during Wednesday’s trading session, investing approximately $4.1 million through its ARKK and ARKG ETFs. Tempus AI, which has seen its stock decline 21% year-to-date in 2026, now constitutes the third-largest holding in the ARK Innovation ETF, representing about 5% of the fund’s total assets. The firm’s acquisition appears timed as a value-buying opportunity amid the stock’s recent pullback. Meta faced multiple challenges on Wednesday, including a jury ruling that found the company and Google’s YouTube negligent for operating platforms that harmed minors in a landmark social media addiction lawsuit. Both firms plan to appeal the verdict.#ark_invest #meta #roku #cathie_wood #tempus_ai
